Overview

Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate. Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular edema associated with uveitis.

Indication

肾上腺皮质激素类药。主要用于过敏性与自身免疫性炎症性疾病。由于本品潴钠作用较弱，故一般不用作肾上腺皮质功能减退的替代治疗。

Associated Conditions

Acne
Acne Vulgaris
Acute Gouty Arthritis
Allergic Contact Dermatitis
Allergic Rhinitis (AR)
Allergic Skin Reaction
Alopecia Areata (AA)
Ankylosing Spondylitis (AS)
Aphthous Stomatitis
Asthma
Atopic Dermatitis
Autoimmune Hemolytic Anemia
Berylliosis
Bullous dermatitis herpetiformis
Chronic Eczema
Chronic Inflammatory Skin Diseases
Congenital Adrenal Hyperplasia (CAH)
Congenital Hypoplastic Anemia
Contact Dermatitis
Crohn's Disease (CD)
Dental Cavity
Dermatitis
Dermatomyositis (DM)
Diaper Rash
Discoid Lupus Erythematosus (DLE)
Edema of the cerebrum
Epicondylitis
Erythroderma
Fungal Infections
Fungal infectious disorders of the Beard
Fungal skin infection
Gingivitis
Haemorrhoids
Hemangiomas
Hypercalcemia
Inflammation of Mouth
Intertrigo
Itching of the Anus
Itching of the External Genitalia
Itching of the Foot
Itching of the genitals
Itching of the hand
Juvenile Idiopathic Arthritis (JIA)
Keloids Scars
Leukemias
Lichen Planus (LP)
Lichen simplex chronicus
Lymphoma
Macular Edema
Mycosis Fungoides (MF)
Mycotic Eczema
Necrobiosis lipoidica diabeticorum
Neurodermatitis
Nummular Dermatitis
Ocular Inflammation
Ophthalmia, Sympathetic
Oral Erosive Lichen Planus
Otitis Externa
Pemphigus
Pericarditis
Polymyositis
Postherpetic Neuralgia
Primary adrenocortical insufficiency
Proteinuria
Psoriasis Vulgaris (Plaque Psoriasis)
Psoriatic Arthritis
Psoriatic plaque
Pure Red Cell Aplasia
Purulent Wounds
Pyoderma caused by susceptible bacteria
Regional Enteritis
Rheumatoid Arthritis
Ringworm Folliculitis
Seborrheic Dermatitis
Seborrheic Dermatitis, Eczematous
Secondary Impetiginization
Secondary adrenocortical insufficiency
Secondary thrombocytopenia
Serum Sickness
Skin chapped
Stomatitis, Denture
Synovitis
Systemic Lupus Erythematosus
Temporal Arteritis
Tinea Corporis
Transfusion Reactions
Trichinosis
Tuberculosis (TB)
Ulcerative Colitis
Urticaria
Uveitis
Wound Infections
Acute Bursitis
Acute Multiple sclerosis
Acute Rheumatic heart disease, unspecified
Acute Tenosynovitis
Corticosteroid-responsive dermatoses
Cutaneous candidiasis
Cystic tumour of the ganglia
Exfoliative erythroderma
Granuloma annulare lesions
Idiopathic eosinophilic pneumonias
Non-suppurative Thyroiditis
Oral infections
Oral lesions
Severe Erythema multiforme
Subacute Dermatitis, Eczematous
Symptomatic Sarcoidosis
Ulceration of the mouth
Ulcerative stomatitis

Research Report

Published: Jul 15, 2025

A Comprehensive Monograph on Triamcinolone (DB00620): Pharmacology, Clinical Efficacy, and Safety Profile

Executive Summary

Triamcinolone is a potent, synthetic glucocorticoid of the pregnane steroid class, representing a significant advancement in anti-inflammatory therapy since its initial U.S. Food and Drug Administration (FDA) approval on December 3, 1957.[1] As a derivative of cortisol, it is engineered to maximize anti-inflammatory and immunosuppressive activity while minimizing the mineralocorticoid effects associated with earlier corticosteroids.[3] Its primary clinical value lies in its ability to powerfully modulate the immune system and control inflammation across a wide spectrum of diseases.

The pharmacological activity of Triamcinolone is mediated through its function as a high-affinity agonist for intracellular glucocorticoid receptors.[1] Upon binding, the activated drug-receptor complex translocates to the nucleus, where it modulates gene expression. This genomic mechanism has a dual effect: it upregulates the synthesis of anti-inflammatory proteins, such as lipocortin-1, and simultaneously represses the transcription of pro-inflammatory genes by inhibiting key pathways involving transcription factors like nuclear factor-kappa B (NF-κB). The net result is a profound suppression of the inflammatory cascade, including the inhibition of critical mediators like prostaglandins, leukotrienes, and a host of pro-inflammatory cytokines.[6]

Continue reading the full research report

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Efficacy of Topical Glucosamine Versus Corticosteroid in Oral Lichen Planus	2025/08/11	NCT07114016	Not Applicable	Completed	Future University in Egypt
Efficacy of Coconut Gel Compared to Corticosteroid Gel in the Management of Oral Lichen Planus	2025/08/03	NCT07100145	Not Applicable	Not yet recruiting	Ain Shams University
Efficacy and Safety of Intralesional 5-Fluorouracil and Triamcinolone Acetonide in Keloids and Hypertrophic Scars	2025/06/24	NCT07034482	N/A	Completed	Maharajgunj Medical Campus
Bevacizumab Versus Triamcinolone Acetonide for the Treatment of Keloids.	2025/06/10	NCT07014280	Phase 4	Active, not recruiting	Kasr El Aini Hospital
Effects Of Intra-Operative Intra-Articular Cocktail Injection In Patella Open Reduction And Internal Fixation	2025/06/05	NCT07006168	Phase 4	Recruiting	The University of Hong Kong
Efficacy of Topical Cannabidiol for Eczema	2025/05/29	NCT06994520	Phase 2	Active, not recruiting	Khon Kaen University
A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip	2025/05/18	NCT06977568	Phase 2	Recruiting	Pacira Pharmaceuticals, Inc
Additional Effect of Steroid on Hyaluronic Acid in Subdeltoid Bursitis	2025/04/20	NCT06935877	Phase 4	Not yet recruiting	Shin Kong Wu Ho-Su Memorial Hospital
Comparison of Intralesional Triamcinolone Versus Verapamil for Keloid Treatment	2025/03/27	NCT06897969	Phase 4	Not yet recruiting	Nishtar Medical University
The Effectiveness of Intralesional Botulinum Toxin A and Triamcinolone Acetonide Injections in Keloid Treatment	2025/02/07	NCT06814288	Phase 2	Active, not recruiting	Universitas Padjadjaran

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Triamcinolone Acetonide	Macleods Pharmaceuticals Limited	33342-329	TOPICAL	1 mg in 1 g	7/1/2023
NYSTATIN AND TRIAMCINOLONE ACETONIDE	NuCare Pharmaceuticals,Inc.	68071-2491	TOPICAL	1 mg in 1 g	8/4/2021
Triamcinolone Acetonide	MICRO LABS LIMITED	42571-385	TOPICAL	1 mg in 1 mL	8/10/2021
Nystatin and Triamcinolone Acetonide	Alembic Pharmaceuticals Inc.	62332-606	TOPICAL	1 mg in 1 g	12/12/2023
TRIDERM	Crown Laboratories	0316-0175	TOPICAL	5 mg in 1 g	10/24/2023
Nystatin and Triamcinolone Acetonide	Bryant Ranch Prepack	63629-2495	TOPICAL	1 mg in 1 g	2/15/2022
NIACINAMIDE 4% / TRIAMCINOLONE ACETONIDE 0.1%	Sincerus Florida, LLC	72934-2166	TOPICAL	0.1 g in 100 g	5/13/2019
Triamcinolone Acetonide	NorthStar Rx LLC	16714-150	INTRA-ARTICULAR, INTRAMUSCULAR	400 mg in 10 mL	1/23/2024
Triamcinolone Acetonide	Physicians Total Care, Inc.	54868-6270	NASAL	55 ug in 1 1	9/27/2011
TRIAMCINOLONE ACETONIDE	Bryant Ranch Prepack	63629-2407	TOPICAL	0.147 mg in 1 g	2/23/2021

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
ECOCORT CREAM	HOE PHARMACEUTICALS SDN BHD	SIN10246P	CREAM	0.1%w/w	10/9/1998
ORREPASTE 0.1% w/w	HOE PHARMACEUTICALS SDN BHD	SIN11484P	PASTE	0.1% w/w	4/9/2001
ORACORT E DENTAL PASTE	TARO PHARMACEUTICAL INDUSTRIES LTD	SIN04682P	PASTE	0.1% w/w	6/13/1990
SHINCORT I.M. INJECTION 40 mg/ml	YUNG SHIN PHARMACEUTICAL IND CO LTD	SIN05787P	INJECTION	40 mg/ml	4/26/1991
ORAMEDY PASTE 1 mg/g	DONG KOOK PHARMACEUTICAL CO LTD	SIN04004P	PASTE	1 mg/g	3/20/1990
SHINCORT INJECTION 10 mg/ml	YUNG SHIN PHARMACEUTICAL IND CO LTD	SIN06709P	INJECTION	10 mg/ml	12/3/1991
KENO ORAL PASTE 1 mg/g	T O CHEMICALS (1979) LTD	SIN11853P	PASTE	1 mg/g	3/21/2002
TRIAMCINOLONE ACETONIDE 40 mg/ml	LISAPHARMA SPA	SIN06648P	INJECTION	40 mg/ml	10/24/1991
NASACORT AQ NASAL SPRAY 55 mcg/actuation	RECIPHARM HC LIMITED	SIN10821P	SPRAY	55 mcg/actuation	3/19/1999
ECONAZINE CREAM	Y S P INDUSTRIES (M) SDN BHD	SIN06601P	CREAM	1 mg/g	10/1/1991

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
TRIAMCINOLONE CREAM 0.2% (VIDA)	N/A	MARCHING PHARMACEUTICAL LIMITED	N/A	N/A	5/19/1979
LONGAXON CREAM	N/A	AMERICAN UNICORN LABORATORIES LIMITED	N/A	N/A	1/14/1997
PROMAX CREAM	N/A	AMERICAN UNICORN LABORATORIES LIMITED	N/A	N/A	12/29/2004
MUCOCARE GEL	N/A	VICKMANS LABORATORIES LIMITED	N/A	N/A	11/19/2007
ECONAZINE CREAM	N/A	PT. YUNG SHIN PHARMACEUTICAL INDONESIA	N/A	N/A	10/17/1990
FLUODERMA CREAM	N/A	MARCHING PHARMACEUTICAL LIMITED	N/A	N/A	2/1/1996
TRISONIN AQUEOUS NASAL SPRAY 55MCG/DOSE	N/A	SYNMOSA BIOPHARMA (HONG KONG) COMPANY LIMITED	N/A	N/A	9/26/2022
ROMACOMB CREAM	N/A	EUROPHARM LABORATOIRES COMPANY LIMITED	N/A	N/A	5/22/1992
QUESITAN CREAM	N/A	EUROPHARM LABORATOIRES COMPANY LIMITED	N/A	N/A	10/10/1995
ORIBIOTIC OINT (VET)	N/A	AlfaMedic Limited	N/A	N/A	8/12/1999

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
TRICORTONE 0.02% OINTMENT triamcinolone acetonide 0.2mg/g tube	95812	Aspen Pharmacare Australia Pty Ltd	Medicine	A	7/30/2003
TRICORTONE 0.02% CREAM triamcinolone acetonide 0.2mg/g tube	95811	Aspen Pharmacare Australia Pty Ltd	Medicine	A	7/30/2003
ARISTOCORT 0.02% OINTMENT triamcinolone acetonide 0.2mg/g tube	15123	Aspen Pharmacare Australia Pty Ltd	Medicine	A	9/9/1991
Kenacomb Otic Ointment tube	19201	Aspen Pharmacare Australia Pty Ltd	Medicine	A	9/30/1991
ARISTOCORT 0.02% CREAM triamcinolone acetonide 0.2mg/g tube	15121	Aspen Pharmacare Australia Pty Ltd	Medicine	A	9/9/1991
Kenacort-A 10 10mg/1mL injection ampoule	19204	Aspen Pharmacare Australia Pty Ltd	Medicine	A	9/30/1991
OTOCOMB Otic ear drops bottle	56477	Aspen Pharmacare Australia Pty Ltd	Medicine	A	8/7/1996
KENACORT-A 40 triamcinolone acetonide 40mg/mL injection ampoule	49226	Aspen Pharmacare Australia Pty Ltd	Medicine	A	9/29/1995
Kenacomb Otic ear drops bottle	19200	Aspen Pharmacare Australia Pty Ltd	Medicine	A	9/30/1991
Kenacomb Ointment tube	19197	Aspen Pharmacare Australia Pty Ltd	Medicine	A	9/30/1991

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
ARISTOSPAN SUS 20MG/ML	lederle cyanamid canada inc.	00297151	Suspension - Intra-Articular	20 MG / ML	12/31/1975
TRIADERM CRM 0.025%	Taro Pharmaceuticals Inc	00716952	Cream - Topical	.025 %	12/31/1979
TRIESENCE	novartis pharmaceuticals canada inc	02368676	Suspension - Intravitreal	40 MG / ML	8/22/2012
SCHEINPHARM TRIAMCINE-A INJECT.SUS-40MG/ML	schein pharmaceutical canada inc.	02219271	Suspension - Intramuscular	40 MG / ML	9/20/1996
TRIAMCINOLONE ACETONIDE INJECTABLE SUSPENSION USP	Sandoz Canada, Inc.	02229550	Suspension - Intra-Articular , Intrabursal , Intramuscular	40 MG / ML	3/26/1997
TEVA-TRIACOMB	teva canada limited	00550507	Cream - Topical	1 MG / G	12/31/1992
ARISTOCORT - SYR ORL 0.4MG/ML	glades, division of stiefel canada inc.	02194139	Syrup - Oral	.4 MG / ML	10/10/1996
ARISTOCORT D - CRM TOP 0.025%	glades, division of stiefel canada inc.	02194074	Cream - Topical	.025 %	10/10/1996
ARISTOCORT-TAB 2MG	glades, division of stiefel canada inc.	02194082	Tablet - Oral	2 MG	1/20/1997
KENACOMB CREAM	westwood-squibb, division of bristol-myers squibb canada inc.	01999850	Cream - Topical	1 MG / G	12/31/1965

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

Health Canada Approves Clearside Biomedical's XIPERE for Uveitic Macular Edema Treatment

a month ago

Health Canada has granted approval for XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use in treating uveitic macular edema, expanding the drug's global reach.

Phase III Clinical Trials Reveal Advances in Non-Infectious Uveitis Treatment Options

3 months ago

Multiple phase III trials demonstrate that locally delivered corticosteroid implants, including fluocinolone acetonide and dexamethasone devices, effectively control inflammation in non-infectious uveitis but carry significant risks of glaucoma surgery and cataract formation.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access

Triamcinolone